Prescription Omega-3 Medicines vs Over-the-Counter Supplements
How prescription omega-3 medicines (icosapent ethyl and EPA/DHA ethyl esters) differ from over-the-counter supplements in approved uses, trial evidence, warnings and oversight.
Content last updated . This page has not been medically reviewed.
Quick answer
Two very different kinds of product share the word "omega-3". Prescription omega-3 medicines are FDA-approved drugs with defined uses, warnings and monitoring. Over-the-counter supplements are sold as dietary supplements. NCCIH says several omega-3 products are approved as prescription drugs for very high triglycerides, that their composition is not the same as typical supplements, and that testing and regulation differ, so their effects may not be the same. [1] Results from one kind cannot be assumed for the other.
Never switch between them, and never stop or change a prescribed medicine, without your prescriber.
What the prescription products are
This page uses the generic names. The two US labels we read are for icosapent ethyl (a purified EPA ethyl ester, sold as Vascepa) and omega-3-acid ethyl esters (EPA and DHA, sold as Lovaza). [2][3] Other prescription omega-3 products exist; their labels were not part of this page. For how the two prescription types compare with each other, see icosapent ethyl vs mixed EPA/DHA products.Side by side (United States)
| Prescription medicines | Over-the-counter supplements | |
|---|---|---|
| Approved uses (US labels) | Icosapent ethyl: with maximally tolerated statin therapy to reduce cardiovascular events in adults with triglycerides of 150 mg/dL or higher and established cardiovascular disease, or diabetes with 2 or more additional risk factors; and, with diet, to lower triglycerides of 500 mg/dL or higher. EPA and DHA ethyl esters: with diet, to lower triglycerides of 500 mg/dL or higher in adults. [2][3] | Sold as dietary supplements. Under US law, manufacturers and distributors are responsible for evaluating the safety and labeling of their products before marketing; FDA can act against an adulterated or misbranded product after it reaches the market. [4] |
| Daily amount on the label | 4 grams a day for both products (label directions, not advice for any person). [2][3] | Varies by product; the EPA plus DHA per serving is on the label. See how to read a fish oil label. |
| Monitoring on the label | Icosapent ethyl: assess lipid levels before starting; ALT and AST checks in liver impairment. EPA and DHA esters: periodic triglyceride and LDL cholesterol checks, and ALT/AST checks in liver impairment. [2][3] | Not described in the sources we read. |
What the labels say about limits
- EPA and DHA ethyl esters state that the effect on the risk of pancreatitis, and on cardiovascular mortality and morbidity, has not been determined. [3]
- Icosapent ethyl states that its effect on pancreatitis risk in severe hypertriglyceridemia has not been determined. [2]
- Neither label has established safety and effectiveness in children. [2][3]
What the trials show, and what they do not
Evidence label: prescription-product trial results; do not transfer to supplements.- REDUCE-IT gave 4 g a day of icosapent ethyl or placebo to 8,179 statin-treated adults with raised triglycerides and heart disease or diabetes. A primary event occurred in 17.2% vs 22.0% (hazard ratio 0.75). Atrial fibrillation or flutter hospitalization was 3.1% vs 2.1%. The trial was funded by the manufacturer. [5]
- STRENGTH gave 4 g a day of an EPA and DHA carboxylic acid product or corn oil to 13,078 similar high-risk adults. Primary events were 12.0% vs 12.2% (hazard ratio 0.99), and the trial was stopped early. Stomach side effects were 24.7% vs 14.7%. [6]
- Why they differ. The sources we read do not explain why these two prescription trials had different results; the products and comparators differed.
- Over-the-counter fish oil. In VITAL (1 g a day of marine omega-3, general adults) the main outcome was not significantly lower than placebo. [7] Cochrane found little or no effect on overall cardiovascular events. [8]
- Head-to-head. Proper evidence not found. A title search of PubMed on 2026-10-23 for randomized trials comparing icosapent ethyl with over-the-counter fish oil or supplements returned no records. That is a narrow search, not proof that none exist.
For triglycerides, the American Heart Association science advisory covers prescription products at 4 g a day; see omega-3 and high triglycerides.
Frequently asked questions
Can I use fish oil instead of a prescription omega-3?
Not on your own. NCCIH says the effects of prescription products may not be the same as those of supplements. [1] Ask your prescriber.
What amount do the prescription labels give?
Both US labels give 4 grams a day as the label amount. That is a prescribing instruction for approved uses, not a general recommendation. [2][3]
Are prescription omega-3 medicines free of side effects?
No. The labels warn about atrial fibrillation or flutter, bleeding and possible fish or shellfish allergy reactions. [2][3]
Do prescription omega-3 medicines prevent heart attacks?
Only one product has that approved use. The icosapent ethyl label lists it for specific high-risk statin users, and the EPA and DHA label says its effect on cardiovascular mortality and morbidity has not been determined. [2][3]
Who oversees supplements compared with medicines?
For supplements, FDA says firms must evaluate safety and labeling before marketing and FDA can act after a product reaches the market. [4] Prescription products carry FDA-approved labeling, as the labels cited here show. [2]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Warnings on the labels
- Atrial fibrillation or flutter. In the cardiovascular trial of 8,179 people, atrial fibrillation or flutter needing hospitalization occurred in 127 (3%) on icosapent ethyl vs 84 (2%) on placebo; the risk was higher in people with a history of atrial fibrillation. [2] The EPA and DHA label also describes a possible association with more frequent recurrences of symptomatic atrial fibrillation or flutter in people who already have it. [3] See fish oil and atrial fibrillation.
- Bleeding. In the same trial, 482 (12%) on icosapent ethyl had a bleeding event vs 404 (10%) on placebo, and bleeding was more common with aspirin, clopidogrel or warfarin. [2] See fish oil, blood thinners and bleeding risk.
- Fish and shellfish allergy. Both products come from fish oil. The labels say it is not known whether people with fish or shellfish allergy are at increased risk of an allergic reaction. [2][3] If you have a known allergy, ask your prescriber before use.
- Pregnancy and breastfeeding. Both labels say the available data are insufficient to identify a drug-associated risk, and that omega-3 fatty acids are found in human milk. [2][3] A prescriber weighs this with you.
Safety and who to ask
Prescription use comes with checks that supplements do not have. If you have high triglycerides or heart disease, ask your prescriber or pharmacist before adding any over-the-counter omega-3, because the two can overlap. Tell every clinician about all products you take, including before surgery. See medication interactions, how supplements are regulated and talking with a health professional. Product quality varies; see quality testing and certifications.
References
- NCCIH, Omega-3 Supplements: What You Need To Know. Read 2026-10-23.
- FDA-approved prescribing information for icosapent ethyl capsules (Vascepa), label revised 3/2026, DailyMed. Read 2026-10-23.
- FDA-approved prescribing information for omega-3-acid ethyl esters (Lovaza), DailyMed. Read 2026-10-23.
- FDA, Dietary Supplements. Read 2026-10-23.
- Bhatt DL et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med 2019. Read 2026-10-23.
- Nicholls SJ et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk (STRENGTH). JAMA 2020. Read 2026-10-23.
- Manson JE et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). N Engl J Med 2019. Read 2026-10-23.
- Abdelhamid AS et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020. Read 2026-10-23.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.